Tucidinostat
Tucidinostat is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against histone deacetylase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
204 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 13 | 61 | 6 | 3 | 10 | 81 |
| T-cell lymphoma peripheral | D016411 | — | — | 9 | 39 | 6 | 3 | 6 | 55 |
| T-cell lymphoma | D016399 | — | — | 9 | 37 | 5 | 3 | 7 | 53 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 5 | 21 | 2 | 1 | 4 | 29 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 3 | 22 | 3 | — | 1 | 23 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 16 | 2 | — | 3 | 21 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 7 | 12 | 1 | — | — | 13 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 2 | 7 | 3 | — | — | 7 |
| Colorectal neoplasms | D015179 | — | — | 1 | 3 | 2 | — | 1 | 7 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 5 | 1 | — | — | 6 |
| Lymphoid leukemia | D007945 | — | C91 | 1 | 4 | 1 | — | — | 4 |
| Melanoma | D008545 | — | — | 1 | 1 | 1 | — | 1 | 3 |
| T-cell leukemia | D015458 | — | — | — | 2 | 2 | — | — | 2 |
| B-cell leukemia | D015448 | — | — | — | 1 | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | 14 | — | — | 1 | 15 |
| Myeloid leukemia | D007951 | — | C92 | 2 | 14 | — | — | 1 | 15 |
| B-cell lymphoma | D016393 | — | — | — | 12 | — | — | 3 | 15 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 7 | — | — | — | 7 |
| Carcinoma | D002277 | — | C80.0 | 2 | 7 | — | — | — | 7 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | 5 | — | — | 1 | 6 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 6 | — | — | — | 6 |
| Immunoblastic lymphadenopathy | D007119 | EFO_1001350 | C86.5 | — | 4 | — | — | 1 | 5 |
| Healthy volunteers/patients | — | — | — | 2 | 4 | — | — | — | 4 |
| Recurrence | D012008 | — | — | 2 | 4 | — | — | — | 4 |
Show 45 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | — | — | — | 1 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemophagocytic lymphohistiocytosis | D051359 | — | D76.1 | — | — | — | — | 1 | 1 |
| Residual neoplasm | D018365 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tucidinostat |
| INN | tucidinostat |
| Description | Chidamide is a member of benzamides. |
| Classification | Small molecule |
| Drug class | enzyme inhibitors: histone deacetylase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 743420-02-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3621988 |
| ChEBI ID | — |
| PubChem CID | 12136798 |
| DrugBank | DB06334 |
| UNII ID | 87CIC980Y0 (ChemIDplus, GSRS) |
Target
Agency Approved
HDAC1
HDAC1
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,711 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
132 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use